Pharmaceuticals 2010, 3(9), 2884-2899; doi:10.3390/ph3092884
Review

Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?

Aaron C. Gerlach* email and Jeffrey L. Krajewskiemail
Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA
* Author to whom correspondence should be addressed.
Received: 19 August 2010; in revised form: 25 August 2010 / Accepted: 1 September 2010 / Published: 1 September 2010
PDF Full-text Download PDF Full-Text [194 KB, uploaded 1 September 2010 10:56 CEST]
Abstract: Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2nd and 3rd generation AEDs as well as compounds in development with novel mechanisms of action.
Keywords: epilepsy; antiepileptic; AED; seizure; anticonvulsant

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Gerlach, A.C.; Krajewski, J.L. Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals 2010, 3, 2884-2899.

AMA Style

Gerlach AC, Krajewski JL. Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals. 2010; 3(9):2884-2899.

Chicago/Turabian Style

Gerlach, Aaron C.; Krajewski, Jeffrey L. 2010. "Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?" Pharmaceuticals 3, no. 9: 2884-2899.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert